LifeSci Advisors, LLC

We’re #hiring a new $2bn Healthcare Growth Venture Fund | (Senior) Associate in Austin, Texas Metropolitan Area. Apply today or share this post with your network.

Join Rectify Pharma for a virtual R&D event on Thurs. Nov. 21 at 11am ET, featuring key opinion leaders who will discuss unmet needs in hepatobiliary diseases, how its lead development candidate RTY-694 is advancing to the clinic, and how Rectify’s small molecule positive functional modulator (PFM) offers a differentiated approach to address the core pathophysiology of primary sclerosing cholangitis and multiple hepatobiliary diseases. Register here: https://lnkd.in/gQaGHrmg

Join Grace Therapeutics, Inc. (#GRCE) for a virtual KOL event on Wed, Nov. 20 at 2pm ET, featuring Abhishek Ray, MD (University Hospitals) and Andrew Webb, PharmD, BCCCP (Massachusetts General Hospital), who will discuss the high unmet medical need and current treatment landscape for patients suffering from aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency. Register here: https://bit.ly/3YBk4Mn

Join Helio Genomics on Mon, Nov. 18 at 5pm PT for an exclusive evening of networking & cocktails with company management at #AASLD The Liver Meeting in San Diego. Chief Medical Advisor, Richard Van Etten, MD, PhD, will be present to discuss Helio’s CLiMB trial, recent data on its methylation model for tumor aggressiveness, and other pipeline products for liver cancer. Register here: https://bit.ly/3Al4EE4

Don't miss it! Tune into the virtual KOL event hosted by Adaptimmune (#ADAP) on Mon, Nov. 18 at 2:30 pm ET, featuring Dr. Sandra P. D’Angelo, M.D. (Memorial Sloan Kettering Cancer Center) who will discuss the current treatment landscape for patients with sarcoma. Register here: https://bit.ly/3Aeh2FY

Join INmune Bio Inc. (#INMB) for a virtual KOL event on Thurs, Nov. 7 at 1pm ET featuring Prof. Judith Jaeger, PhD, MPA and Sarah Barnum, PhD, ABPP from CognitionMetrics who will join CJ Barnum, PhD, VP of CNS Drug Development, to discuss the unmet need and current treatment landscape for patients with Early Alzheimer’s Disease (AD) with biomarkers of elevated neuroinflammation. Register here: https://bit.ly/48u8mYF

Join us on Thursday, November 14th at 12:30pm ET for the latest "Lunch with LifeSci" webinar featuring Compass Therapeutics Inc. (#CMPX). CEO Thomas Schuetz, MD, PhD will discuss the development of their innovative bispecific antibody, CTX-009, a dual-targeting therapy designed to block tumor growth and progression in patients with biliary tract cancer (BTC). Register here: https://bit.ly/3YrDzXS

Join Vera Therapeutics, Inc. (#VERA) for a virtual investor event TOMORROW, Oct. 28 at 8 am ET, featuring Jonathan Barratt, MD, PhD, FRCP (University of Leicester), along with Vera’s management team, who will discuss long-term data from the Phase 2b ORIGIN trial of atacicept in immunoglobulin A nephropathy (IgAN), showing atacicept stabilized kidney function through 96 weeks. Register here: https://bit.ly/4hnZPdW

Join Humacyte (#HUMA) for a virtual KOL event with a Q&A session on Thurs, Oct. 31 at 8am ET, featuring Charles Keith Ozaki, MD (Brigham and Women’s Hospital), Mohamad Anas Hussain, MD, PhD (Brigham and Women’s Hospital), and Timmy Lee, MD, MSPH (University of Alabama at Birmingham), who will discuss the current treatment landscape and unmet need for improved arteriovenous (AV) access in hemodialysis patients. Register here: https://bit.ly/3UlIOae

Tune into the Inmagene Biopharmaceuticals virtual KOL event on Thurs, Oct. 31 at 10am ET with Jonathan Silverberg, MD, PhD, MPH, Maryanne Senna, MD, and Yufang Lu, MD, PhD, who will discuss the potential role of anti-OX40/OX40L monoclonal antibodies (mAbs) in the treatment of atopic dermatitis (AD) and alopecia areata (AA). Register here: https://bit.ly/4esqDYt